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Symptomatic ileofemoral DVT after onset of oral
contraceptive use in women with previously
undiagnosed May-Thurner Syndrome
Erin H. Murphy, MD,a Charles M. Davis, BS,a Janna M. Journeycake, MD,b
R. Patrick DeMuth, ThM, RVT,a and Frank R. Arko, MD,a Dallas, Tex
Objective:May-Thurner syndrome is characterized by left common iliac obstruction secondary to compression of the left
iliac vein by the right common iliac artery against the fifth-lumbar vertebra. This anatomic variant results in an increased
incidence of left-sided deep venous thrombosis (DVT). Furthermore, while a preponderance of left-sided DVT has been
demonstrated in women during pregnancy and oral contraceptive use, patients are not typically screened for this
condition after developing a left-sided DVT. As anticoagulation alone is ineffective for DVT treatment in the setting of
May-Thurner anatomy, more aggressive treatment is warranted. Failure to diagnosis this condition predisposes these
women to the unnecessary risks of recurrent DVT and post-thrombotic syndrome.
Methods: We present the occurrence of 7 adolescent patients with previously undiagnosed May-Thurner syndrome who
presented with DVT after the initiation of oral contraceptive steroids (OCP) use. All 7 patients elected to proceed with
mechanical thrombolysis/catheter based thrombolysis followed by endovascular stenting and were postoperatively
treated with 6 months of warfarin.
Results: Mean patient age was 18.3  3.3 years (range, 16-24 years). Mean time to presentation after initiation of OCP
was 5 weeks (range, 2-10 weeks). Mean time to intervention was 16.8 days (range, 10-24 days). All patients were treated
with mechanical thrombectomy. Our rate of intraoperative clot resolution was 100%. All 7 patients were treated with self
expanding nitinol stents after angioplasty of the iliac vein stenosis with resolution of the stenotic segment. Primary stent
patency is 100% (7/7). Mean follow-up time is 13 13.84 months (range, 6-42 months). There have been no long-term
complications related to surgical treatment or anticoagulation. All 7 patients have experienced resolution of left leg
swelling and pain and have no evidence of post-thrombotic syndrome or DVT recurrence to date.
Conclusions: Women on OCPs presenting with left-sided iliofemoral DVT should be screened for hypercoagulable
disorders and underlying May-Thurner anatomy. Treatment of May-Thurner syndrome should include thrombolysis/
thrombectomy and anticoagulation for current DVT in addition to angioplasty and stenting of the underlying
obstruction. (J Vasc Surg 2009;49:697-703.)May-Thurner syndrome is a disease entity first de-
scribed by May and Thurner in 1957 and is characterized
by the occurrence of left common iliac obstruction second-
ary to compression of the left iliac vein by the right com-
mon iliac artery against the fifth lumbar vertebra.1 Chronic
pulsatile compression results in intimal proliferation within
the iliac vein. This anatomic variant can result in an in-
creased incidence of deep venous thrombosis (DVT). Pa-
tients may go on to develop pulmonary emboli and symp-
toms of post-thrombotic syndrome characterized by
chronic edema, pain, hyperpigmentation, varicosities, and
skin ulceration.
The incidence of May-Thurner syndrome is likely un-
derestimated since many patients are initially asymptom-
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doi:10.1016/j.jvs.2008.10.002atic. While the estimated incidence of this underlying ana-
tomic variant is approximately 22%-24%, the actual risk of
progression to thrombosis is believed to be influenced by
other factors affecting a patient’s coagulation profile.1-3
The increased risk of DVT in patients taking oral con-
traceptives (OCP) has been well reported. This risk has also
been demonstrated in the peri-partum period in otherwise
healthy young women.4,5 Furthermore, a left-sided pre-
dominance of DVT has been demonstrated in both preg-
nancy and OCP use.6-10 However, while the possibility of
iliac vein compression by the right iliac artery has been alluded
to as a cause of this laterality of DVT occurrence, there have
been no reports of women exposed to extra estrogens being
screened for this particular condition after developing a left-
sided DVT. It seems likely that this condition is under diag-
nosed and under treated in these women.
As anticoagulation alone has proven to be an ineffective
sole treatment regimen for iliofemoral DVT in the presence
of underlying iliofemoral venous obstruction,10-12 more
aggressive treatment is warranted. Angioplasty and endo-
vascular stenting of the obstruction has proven to be the
most efficacious therapy in this population.13-22 Failure to
diagnosis this condition predisposes these women to the
unnecessary risks of recurrent DVT and post-thrombotic
syndrome.
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patients with previously undiagnosed May-Thurner syn-
drome who presented with DVT after the initiation of oral
contraceptive steroid use.
METHODS
Patients. Between January 2005 and February 2008,
7 females with previously undiagnosed May-Thurner syn-
drome presented with DVT after the initiation of oral
contraceptive steroids (OCP) use. Patient data was cap-
tured prospectively in a vascular patient database and
records were reviewed retrospectively. Data collected and
reviewed included: patient demographics, use of oral con-
traceptive steroids (OCP), results of hypercoagulable work-
up, procedural details, lytic used, clinical outcomes, and
follow-up. All patients were treated at our tertiary academic
medical center.
Initial Evaluation. Diagnosis of DVT was made by
patient history, physical exam and duplex ultrasound (HDI
5000 Sonos CT; Phillips Medical Systems, Bothell, Wash).
Vein wall compression was examined throughout the
length of bilateral lower extremities. Regions of noncom-
pression or partial compression were evaluated in the trans-
verse and sagittal planes in gray scale and the residual lumen
was assessed under color Doppler imaging.
All patients underwent screening for hypercoagulable
disorders before treatment including screening for Protein
C, Protein S and antithrombin III deficiency, presence of
lupus anticoagulant, anticardiolipin antibody, anti-2 gly-
coprotein antibody and antiphosphotidyl serine antibody,
factor V Leiden mutation, prothrombin G20210A, eleva-
tion of lipoprotein A, and hyperhomocysteinemia.
Treatment. At the time of diagnosis, all patients un-
derwent initial anticoagulation with subcutaneous low-
molecular weight heparin or intravenous heparin. This was
followed by operative intervention for acute DVT in all
patients.
Retrievable IVC Filters (G2 IVC filter, C.R. Bard,
Tempe, Ariz) were used to protect against embolization
during intervention.23,24 Filters were deployed in standard
fashion from the contralateral groin at the level L2/L3
under fluoroscopic guidance at the start of the procedure.
Access for venography and intervention was obtained
via the ipsilateral popliteal vein under ultrasound guidance
in 6 patients and through the ipsilateral common femoral
vein in 1 patient who had thrombus restricted to the iliac
vein. An 8F sheath was used with a 0.035 guidewire and
catheter (Glidewire and Glidecatheter, Boston Scientific,
Natick, Mass) to cross the thrombus. Venography and
intravascular ultrasound (IVUS) were used to confirm the
presence of iliofemoral DVT and assess extent of thrombus
burden.
All patients underwent local infusion of thrombolytics
(TNK-T-PA) using the AngioJet with power-pulse spray
technique or pharmacomechanical thrombolysis with the
Trellis-8 (Bacchus Vascular, Santa Clara, Calif) during the
initial procedure or following overnight thrombolysis.The AngioJet catheter system is comprised of a single-
use catheter, a pump set, and a drive unit. The catheter is
advanced over the guidewire through the thrombus. The
clot is infused with 5-10 mg of thrombolytic (TNK-tPA) in
50 ml of isotonic chloride solution as the catheter is slowly
withdrawn. The lytic is left in place for 10 minutes after
which this system is used in standard fashion. The drive unit
generates 10,000 psi of pulsatile infusion flow with high
velocity jets resulting in a localized low-pressure zone and
thrombus maceration and aspiration.
The Trellis-8 system consists of a single-use catheter, a
dispersion wire, and an integral drive unit. The catheter is
inserted through the 8F sheath, over a guidewire, and
through the thrombus. The proximal and distal balloons
are inflated and 5-10 mg of TNK-tPA is infused. The
dispersion wire is then connected to the drive unit and
rotated within the clot up to 3500 rpm causing localized
clot lysis. After 10 minutes, the clot is aspirated.
Patients with residual thrombus underwent overnight
catheter directed thrombolysis in the intensive care unit
using Tenecteplase (TNK-T-PA; Genentech Inc, South
San Francisco, Calif) at a rate of 0.25mg/hour. Fibrinogen
levels were obtained at baseline then every 6 hours during
infusion therapy. The fibrinogen level was maintained at
more than 100 mg/dL.
Venography and intravascular ultrasound were used at
the termination of the procedure, or after overnight throm-
bolysis, to assess thrombus reduction and evaluate remain-
ing iliac vein compression. Angioplasty was performed over
the stenotic segment with 10  40mm (n  5), 8  40
(n  1), and 12  40 (n  1) balloon catheters. This was
followed by placement of nitinol self-expanding Wallstents
(n 4; Boston Scientific, Maple Grove, Minn.) or Protege
EverFlex stents (n  3; EV3, Minneapolis, Minn). Stents
were profiled post-placement and completion venography
and IVUS were used to confirm stent patency and resolu-
tion of stenosis.
Postoperative Care and Follow-up. Postoperatively,
patients were anticoagulated with low-molecular-weight
heparin until therapeutic on Coumadin (goal International
Normalized Ratio 2.0-3.0). Coumadin is continued in all
patients for 6 months following the procedure. All patients
are maintained on lifelong aspirin for stent patency. Pa-
tients are followed with serial ultrasound and clinical exams
at 1 and 6 months and then annually to assess patency and
valvular function in the lower extremities. Assessment of
valve function of the deep veins (lower superficial femoral
vein and popliteal vein) is performed postoperatively with
pulse wave samples obtained in the sagittal plane and calf
augmentation maneuvers. Evidence of valve dysfunction
and venous reflux included reversal of venous flow lasting
more than .75 seconds during valsalva or following initial
flow augmentation during manual compression of the dis-
tal limb.25
RESULTS
Patients. Seven females with a mean age of 18.3 3.3
years (range, 16-24 years) presented with left iliofemoral
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lateral left leg swelling and pain. Mean time to presentation
after initiation of OCP was 5 weeks (range, 2-10 weeks).
Three patients had Factor V Leiden mutation discovered
during hypercoagulable work-up. The remaining 4 patients
had no clotting abnormalities (Table I).
Five patients underwent preoperative duplex ultra-
sound at our institution. The remaining 2 women were
referred after initial diagnosis and initiation of anticoagula-
tion. All 5 women imaged at our institution had evidence of
iliac vein obstruction on initial venous ultrasound as dem-
onstrated by the following findings in all patients: smaller
caliber vessel observed in the transverse view at the level of
crossing by the right iliac artery with asymmetry in compar-
ison to the contralateral vessel at the same level, continuous
flow through the stenotic segment and proximal to this
segment (rather than phasic flow) during respiration, ele-
vated flow velocity, and diminished responses during val-
salva and compression maneuvers (Fig 1).
Thrombus involvement was isolated to the iliac vein in
2 patients and extended throughout the iliofemoropopli-
teal venous segments in the remaining 5 patients. Two of
the 5 patients with iliofemoropopliteal thrombosis had clot
extension into the inferior IVC. (2) All patients had high
grade focal stenosis and/or complete obstruction at the
level of the left iliac vein confirmed by venography and
IVUS. Mean time to intervention from time of symptom
onset was 16.8 days (range, 10-24 days).
Five patients underwent placement of optional vena
caval filters placed prior to intervention. Two patients had
filters placed at outside institutions prior to presentation for
operative intervention.
Several patients required preoperative (2) or postoper-
ative chemical thrombolysis (1) in the ICU and were
treated with tenecteplase at a rate of 0.25mg/hr for a mean
infusion time of 9.8 hours (range, 6-18 hours). Indications
for chemical thrombolysis were heavy clot burden (il-
eofemoropopliteal clot with extension into the IVC) at
initial operation (2) and residual thrombus after pharmo-
mechanical thrombectomy (1). The 4 remaining patients
were treated in a single setting with a mean procedural time
of 151 minutes.
Patients were treated with the mechanical thrombec-
tomy (pulse-power spray technique) (5), pharmacome-
Table I. Demographics and follow-up
Patient #
Age
(years) Hypercoagulable disorder
Follow-up
(months)
1 16 Factor V Leiden - Heterozygote 22
2 16 Factor V Leiden - Heterozygote 11
3 16 None 12
4 24 Factor V Leiden - Heterozygote 8
5 22 None 45
6 17 None 9
7 17 None 6chanical thrombolysis (1), or both (1). The later patientunderwent pharmacomechanical thrombolysis resulting in
only 60% clot resolution followed by clot aspiration with
the pulse power spray technique without additional lytics.
This resulted in complete clot resolution. Mean intraoper-
ative thrombolytic dose was 8  3.65mg of tenecteplase.
All 7 patients were treated with self expanding nitinol
stents after angioplasty of the iliac vein stenosis with reso-
lution of the stenotic segment. A total of 10 stents were
placed in 7 patients with diameters ranging from 14-16mm
(3-16 mm, 7-14 mm). Stent lengths ranged from 4 cm to 8
cm. All stents were placed above the inguinal ligament. In 2
patients with stenosis encroaching on the iliac vein conflu-
ence, stents were extended into the IVC to prevent early
restenosis. Overall technical success was 100% with com-
plete thrombus removal and stent patency documented at
the end of the procedure in all patients (7/7).
There was one early complication which consisted of a
retroperitoneal hemorrhage in a 17-year-old female. This
patient had undergone chemical thrombolysis for approxi-
mately 6 hours followed by AngioJet aspiration thrombec-
tomy and stent placement. She was continued on heparin
drip. On postoperative day 2, she developed abdominal
pain and had a decrease in her hematocrit requiring 2 units
of blood. She underwent a computed tomography scan of
the abdomen, which confirmed a retroperitoneal hemor-
rhage. Heparin was held for 24 hours during which time
her hematocrit remained stable. She was again heparinized
and transitioned to Coumadin without further complica-
tions.
Mean follow-up time is 16.1  13.73 months (range,
6-45 months). Median follow-up was 11 months. All IVC
filters have been removed. Mean time to filter removal was
5.1 3.4 weeks (range, 2-10weeks post-initial procedure).
Six of the 7 patients experienced resolution of symptoms
with documentation of patent venous segments/stents on
follow-up ultrasound with preservation of lower extremity
valve function (Figs 2 and 3). One patient complained of
recurrent venous congestion and had residual stenosis of
the external iliac vein on repeat venography. This was
treated with balloon angioplasty and stenting of the exter-
nal iliac vein, overlapping the stent with the previously
placed common iliac stent by 1 cm, with resultant symptom
improvement postoperatively. Primary stent patency is
100% (7/7). While long-term follow-up is not yet available
for most patients, there have been no occurrences of post-
thrombotic syndrome to date.
DISCUSSION
In 1851, Virchow first reported the observation that
left iliofemoral DVT is 5 times more likely to occur than
right sided DVT.26 It was not until nearly a century later
that this laterality in DVT incidence was able to be corre-
lated with its cause. In 1957, May and Thurner described
an anatomic variant in which compression of the left iliac
vein by the right iliac artery led to an increased incidence of
left iliofemoral DVT. This variant was described in 22% of
430 cadavers at time of autopsy.1
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image (A) demonstrates compression of the left common iliac vein (LCIV-no color) at the level of the right common
iliac artery (RCIA-blue). The right common iliac vein (RCIV-blue below) and left common iliac artery (LCIA-yellow)
are also seen in this image. The second image (B) is a long axis gray scale image of the compressed LCIV to the left of
the image at the level of crossing by the RCIA and the normal size vein distally to the right. Image (C) demonstrates
increased velocities near the site of compression with continuous flow during normal respiration. Image (D) shows
continuous flow and lack of response to distal compression.Fig 2. Preoperative (A) and postoperative (B) images of 16-year-old female with May-Thurner syndrome and
left-sided iliofemoropopliteal deep vein thrombosis.
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however, the reported annual DVT incidence is only 1-3
individuals per 1,000 people each year.27 Kim at al sug-
gested that patients with this anatomy progress through 3
distinct stages of disease at variable rates: Stage I is asymp-
tomatic vein compression, Stage II is development of a
venous spur (fibrous vascular lesions within the iliac vein at
the site of compression by the right iliac artery), and Stage
III is development of DVT.2 Progression from an asymp-
tomatic state to a pathological state of DVT development is
not absolute or consistent and is likely influenced by other
factors causing alteration of the patients’ coagulation pro-
file and influencing risk of thrombosis.
Oral contraceptives are estimated to be used by over
100 million women worldwide.28 Although not specifically
evaluated in patients with May-Thurner syndrome, OCP
use has been associated with increased incidence of DVT in
an otherwise young, healthy female population. Vanden-
buroucke et al published a review of oral contraceptive use
and the risk of venous thrombosis and described an overall
net prothrombotic effect of OCPs; an increase in pro-
thrombotic effects, a decrease in normal anticoagulation,
and a neutral effect on fibrinolysis.4 The result is a 3-11 fold
increased risk of DVT in women on OCPs compared with
the general population, with the greatest risk observed in
the first year of use.4,5 While the absolute risk of DVT in
this group is still low, reported as 3-4 per 10,000 person-
years, the vast number of women on oral contraceptives
allows even infrequent complications to affect a large num-
ber of women. In addition, the risk of DVT may be further
accentuated when additional pro-thrombotic risk factors
are present.
One factor known to precipitate DVT in women on
OCP is the presence of hypercoagulable disorders, particu-
larly Factor V Leiden. Patients with Factor V Leiden mu-
tations have a baseline increased risk of DVT approximately
Fig 3. Postoperative Duplex ultrasound image demonstrating re-
lief of venous obstruction, widely patent iliac vein, and phasic
venous flow.7 times that of non-carriers. This is increased by a factor of35 when taking OCPs.5 Screening patients for Factor V
Leiden, a mutation carried by up to 5% of women, prior to
initiating use of OCP, has been debated. The consensus,
mostly due to excessive cost of screening and a low mortal-
ity of DVT in young women, has been to screen only those
patients with a concerning personal or family history. Three
of our 7 patients were diagnosed with Factor V Leiden
heterozygotes during their evaluation for DVT. The mul-
tiple risk factors for DVT in these women (OCP use,
hypercoagulable state, and underlying May-Thurner anat-
omy) were likely additive, significantly increasing ultimate
risk of thrombosis.
The true extent and contribution of variant anatomy in
women who experience DVT after starting oral contracep-
tives is largely unknown and has not been studied. How-
ever, anatomical factors make variant venous anatomymore
likely in women. The increase in lumbar lordosis that
develops during maturation of the female pelvis pushes the
lower lumbar vertebra forward, increasing compression of
the left iliac vein by the right iliac artery. This lordosis is
even further increased in pregnancy.29,30
Furthermore, reports have consistently demonstrated a
sinister predominance of DVT in patients on OCP and
during pregnancy. Gherman et al demonstrated an 81%
preponderance of left sided DVT in 127 women during the
peripartum period.6 Additional studies revealed left-sided
DVT rates during the peripartum period ranging from
75%-82%.7-9 Ginsberg et al similarly reported a 97% left-
sided incidence of DVT occurring during pregnancy (58/
60)7and Berqvist et al noted proximal thrombi (13/17)
and left-sided thrombi (14/17) were predominant in 17
pregnant females with DVT.9 Left laterality of DVT has
further been demonstrated to occur in women on OCP at
similar rates.10 Notably, while the aforementioned reports
all discussed the possibility of May-Thurner anatomy as an
underlying cause of left laterality of DVT, none of these
reports evaluated patients for this condition. Our report
suggests that this syndrome is likely under diagnosed in
women with DVT on OCPS and the above reports may
imply under diagnosis in evaluation of DVT during preg-
nancy/peripartum period as well.
Since the prospective risk of initiating OCP use in
patients with May-Thurner syndrome has not been evalu-
ated thus far, we cannot recommend that women be
screened for this condition prior to initiating OCP use.
However, we do advocate that women on OCP or in the
peripartum period presenting with left-sided DVT be
screened for this condition. Further, while less common, it
should be remembered that underlying venous obstruction
may also present in the right leg and would need to be
addressed in a similar manner when it occurs.
The importance of diagnosing this condition lies in a
distinct need for more aggressive treatment than that re-
quired for typical DVT. Currently, the standard of care for
typical DVT consists of oral anticoagulation. However, in
patients with May-Thurner syndrome, this has proven in-
adequate sole therapy. Despite adequate anticoagulation,
untreated iliac vein obstruction will prevent vessel recana-
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will have continued clot propagation.11,12 Further, long-
term follow-up of patients with iliofemoral DVT and un-
treated obstruction have demonstrated that up to 50%
develop venous claudication, 86% develop venous stasis
ulcers, and all develop chronic leg edema.31 Prevention of
the debilitating late sequlae of post-thrombotic syndrome
including venous claudication, edema, discoloration, pain,
and venous stasis ulcers in otherwise healthy young females
is therefore a primary treatment goal. Anticoagulation
alone does not restore valve function or prevent these
long-term effects.31,32
To adequately treat acute DVT in young women with
underlying May-Thurner syndrome and prevent post-
thrombotic symptoms, we suggest a high suspicion for this
condition along with aggressive surgical management.
Herein we described our approach of thrombolysis/me-
chanical thrombectomy combinedwith angioplasty and stent-
ing of remaining iliac vein stenosis. The feasibility and success
of this technique has been well documented in patients with
iliac vein obstruction and acute DVT. AbuRahma et al dem-
onstrated 1-year primary patency rates of 83% after com-
bined thrombectomy, angioplasty, and stenting, results
well exceeding those obtained with thrombectomy alone (1
year venous patency: 24%).15 Nazarian et al further dem-
onstrated 4-year primary and secondary patency rates of
50% and 75% respectively in patients with iliac vein com-
pression treated with thrombectomy, angioplasty, and stent
placement.16 While the cause of iliac vein compression in
the above studies varied and included pelvic malignancy,
trauma, surgery, pregnancy, and idiopathic causes, this
approach has also been described in patients with isolated
May-Thurner syndrome. Kwak et al evaluated the use of
metallic stents following thrombectomy in 16 patients with
idiopathic May-Thurner anatomy and demonstrated pri-
mary and secondary patency rates of 95% and 100% respec-
tively at 2 years.14 Further, Hartung et al reported primary
and secondary patency rates of 86% and 100% out to 120
months following venous thrombectomy and iliac stenting
for acute DVT in patients with May-Thurner syndrome
(22/35).19
Importantly, the use of thrombolysis/thrombectomy
combined with iliac vein stenting has also been shown to
improve patient outcomes and aid in the prevention of the
sequlae of post-thrombotic syndrome. Patel et al employed
wall stents in 10 patients with May-Thurner syndrome and
reported complete resolution of all symptoms in all pa-
tients. They further reported that follow-up ultrasound
revealed no evidence of valve insufficiency in the femoral or
popliteal veins post-stenting.17
Our results with this technique have been excellent,
with 100% intraoperative clot resolution and 100% primary
stent patency to date. Additionally, all women have experi-
enced complete resolution of left leg swelling and pain and
have preserved valve function on follow-up ultrasound.
While long-term data is not available for all patients, there
have been no occurrences of post-thrombotic syndrome to
date. We had one major morbidity with occurrence of aretroperitoneal hemorrhage in a young women receiving
overnight thrombolysis. This complication is well reported
with lytic use/anticoagulation and occurs in less than 10%
of patients undergoing these procedures. These procedures
require that the patient and surgeon balance the acute
procedural risk of bleeding with the long term risk of
developing post-thrombotic syndrome. The authors feel
that the procedural risk is acceptable in otherwise healthy,
young women but recognize that the risk benefit assess-
ment must be individualized to each patient. Importantly,
there have been no late complications related to surgical
treatment or anticoagulation in these women.
CONCLUSION
Women on OCP presenting with left-sided iliofemoral
DVT should be screened for hypercoagulable disorders and
underlying May-Thurner anatomy. These recommenda-
tions can likely be extended to women during pregnancy
and the peripartum period. Further, when May-Thurner
syndrome is diagnosed, aggressive endovascular manage-
ment should be pursued to prevent thrombus recurrence
and symptoms of post-thrombotic syndrome. The authors
recommend thrombolysis and anticoagulation for current
DVT in addition to angioplasty and stenting of the under-
lying obstruction.
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